The findings suggest that enfortumab vedotin, especially combined with pembrolizumab, offers promising beneficial outcomes in metastatic urothelial carcinoma treatment,” researchers wrote.

Enfortumab vedotin is now available for patients who received prior platinum-containing chemotherapy and a PD-1/L1 inhibitor ...

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with an entire industry chain, announced that the Phase Ib/II clinical study results of the novel Nectin-4-targeting ADC 9MW2821 ...

RHHBY records impressive first-quarter 2025 performance on the back of strong demand for key drugs. The company confirms 2025 guidance.

Using the Ultima Genomics’ (CA, USA) lower-cost WGS platform and the known mutational patterns in patient tumors as a guide, ...

Bicycle Therapeutics targets innovative cancer treatments with potential, like zelenectide pevedotin. Read here for an ...

A copy of the presentation materials can be accessed on the “ Publication ” section of the Company’s website at www.bioatla.com once the presentations have concluded.

Report Ocean published the latest research report on the Urothelial Carcinoma Treatment Market. In order to comprehend a market holistically, a variety of factors must be evaluated, including ...

Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other life-threatening diseases, will present the ...

The following is a summary of “Long-term outcome of radiation therapy for locoregional recurrence of upper tract urothelial ...